COGT ▲ +0.3% - Cogent Biosciences, Inc. $COGT - Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) Cogent Biosciences rose 0.3% following the FDA's acceptance of its new drug application for bezuclastinib, a treatment candidate for advanced systemic mastocytosis. The NDA acceptance is a significant regulatory milestone that allows the FDA to begin its formal review of the drug, potentially moving it closer to market approval. 15-SEP-2026 08:01 AM ET